title: Expression and regulation of constitutive and acute phase serum amyloid A mRNAs in hepatic and non-hepatic cell lines.
abstract: 'Acute phase' and 'constitutive' SAA (A-SAA and C-SAA, respectively) mRNA levels were measured in hepatic and non-hepatic cell lines after treatment with monocyte conditioned medium (MoCM), with or without dexamethasone (Dex). A-SAA mRNAs were detected in MoCM-treated hepatoma cell lines (PLC/PRF/5, HuH7, HepG2, and Hep3B), a fibroblast cell line (MRC5), six epithelial cell lines (RT4/ 31, SW13, Hela Ohio, HCT-8, CaCo2, and KB), and an endothelial cell line ECV304. In KB cells, Dex alone caused a dramatic increase in A-SAA mRNA levels. C-SAA was detected in all hepatic and non-hepatic cell lines. Two differentially regulated size classes of C-SAA mRNA were detected in the hepatoma cell lines. A-SAA mRNA levels were measured in ECV304 cells treated with IL-1 beta, IL-6, TNF alpha and Dex, in various combinations, and revealed different profiles to those seen for hepatic cells. The extent of polyadenylation of A-SAA mRNA in ECV304 and KB cells differed whereas the polyadenylation of C-SAA mRNA remained constant. These data suggest that the parameters that determine the steady state mRNA levels and post-transcriptional regulation of A-SAA and C-SAA mRNAs are different and are cell type specific.
authors.affiliation: Department of Genetics, Trinity College, University of Dublin, Ireland.
authors.forename: D M
authors.initials: DM
authors.lastname: Steel
authors.forename: F C
authors.initials: FC
authors.lastname: Donoghue
authors.forename: R M
authors.initials: RM
authors.lastname: O'Neill
authors.forename: C M
authors.initials: CM
authors.lastname: Uhlar
authors.forename: A S
authors.initials: AS
authors.lastname: Whitehead
mesh_terms: D000210:Acute-Phase Reaction / Q000235:genetics*; D000306:Adrenal Cortex Neoplasms / Q000378:metabolism / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D004847:Epithelial Cells; D004848:Epithelium / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006207:Half-Life; D006367:HeLa Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D007414:Intestinal Neoplasms / Q000378:metabolism / Q000473:pathology; D007624:KB Cells / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000473:pathology; D009000:Monocytes / Q000378:metabolism; D009062:Mouth Neoplasms / Q000378:metabolism / Q000473:pathology; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D009928:Organ Specificity; D012323:RNA Processing, Post-Transcriptional; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000235:genetics; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D000685:Serum Amyloid A Protein / Q000096:biosynthesis* / Q000235:genetics; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D017077:Culture Media, Conditioned; D007375:Interleukin-1; D015850:Interleukin-6; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011994:Recombinant Proteins; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D003907:Dexamethasone